Sage Therapeutic (SAGE)

NASDAQ
46.20
+1.85(+4.17%)
Pre Market
44.85
-1.35(-2.92%)
- Real-time Data
  • Volume:
    614,688
  • Bid/Ask:
    38.41/47.00
  • Day's Range:
    44.81 - 46.28

SAGE Overview

Prev. Close
44.35
Day's Range
44.81-46.28
Revenue
1.11B
Open
45.25
52 wk Range
39.77-98.39
EPS
11.84
Volume
614,688
Market Cap
2.72B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
665,000
P/E Ratio
3.90
Beta
1.88
1-Year Change
-23%
Shares Outstanding
58,811,151
Next Earnings Date
Nov 04, 2021
What is your sentiment on Sage Therapeutic?
or
Market is currently closed. Voting is open during market hours.

Sage Therapeutic News

Sage Therapeutic Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyBuyStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell

Sage Therapeutic Company Profile

Sage Therapeutic Company Profile

Sector
Services
Employees
298

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.

Read More
  • CEO believing in the company's potential. In addition to the value traded far below the real price. I'm still bought
    0
    • The president and CEO of this company bought lots of shares of SAGE for a value of more than a million dollar; i might buy some 100 for hust 4.1K
      0
      • what do you mean Claudio ? is it worths to entry now ?
        0
      • NY Brokers Stock ExchangeYES it is way oversold
        0
    • looking for a support around here but am I dreaming?
      0
      • Stock up before the phase2 dat for Essential tremor SAGE-324 is out
        0
        • 🤑🤑🤑after all this lockdown and toilet paper scarcity depression treatment will be an even more tremendously flourishing business! major depression! not to mention the babies who will born because couples lockdown together!!! postpartum depression!!!great timing for the company to handle the aftermath of coronavirus!!!🚀🚀🚀
          0
          • i will sell at 150great money maker
            1
            • perfect time to enter
              0
              • bought some yesterday . will buy more if it goes below 60 .
                0
                • bought some yesterday . will buy more if it goes below 60 .
                  0
                  • Discounted.
                    0
                    • hi all recommended to buy or not!!
                      0
                      • Daily chart looking like it walked off a cliff, Wil E. Coyote style.
                        0
                        • ooopsie holders
                          0
                          • OK made me lough
                            0
                        • What’s going in with SAGE’s options?
                          0
                          • The share you HAVE to own in your portfolio
                            0
                            • $SAGE Next major milestone is Part B Phase 2 data on SAGE-217. Major Depressive Disorder (MDD). Coming next month, although we did get a preview today. Positive!!! $100 handle easy
                              0
                              Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                              Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.